A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: Processes and requirements

Drug Discovery Today

Volumn 16, Issue 13-14, 2011, Pages 583-593

  Schwarz, Adam J ^a,b   Becerra, Lino ^a,e   Upadhyay, Jaymin ^a   Anderson, Julie ^a   Baumgartner, Richard ^a,c   Coimbra, Alexandre ^a,c   Evelhoch, Jeff ^a,c   Hargreaves, Richard ^a,c   Robertson, Brigitte ^d   Iyengar, Smriti ^a,b   Tauscher, Johannes ^a,b   Bleakman, David ^a,b   Borsook, David ^a,e  

^a MCLEAN HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; STANDARDIZATION;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; QUALITY CONTROL;

EID: 79959758527     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.05.006     Document Type: Review

References (52)

1. D. Borsook CNS response to a thermal stressor in human volunteers and rats may predict the clinical utility of analgesics Drug Dev. Res. 68 2007 23 41 (Pubitemid 46878003)
2. R.A. Leslie, and M.F. James Pharmacological magnetic resonance imaging: a new application for functional MRI Trends Pharmacol. Sci. 21 2000 314 318 (Pubitemid 30642922)
3. D. Borsook A role for fMRI in optimizing CNS drug development Nat. Rev. Drug Discov. 5 2006 411 424
4. P. Schweinhardt Pharmacological FMRI in the development of new analgesic compounds NMR Biomed. 19 2006 702 711 (Pubitemid 44515614)
5. D. Borsook A 'BOLD' experiment in defining the utility of fMRI in drug development Neuroimage 42 2008 461 466
6. D. Borsook Imaging in CNS Drug Discovery and Development: Implications for Disease and Therapy 2010 Springer
7. R.G. Wise, and I. Tracey The role of fMRI in drug discovery J. Magn. Reson. Imaging 23 2006 862 876 (Pubitemid 43825441)
8. D.F. Wong The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology 34 2009 187 203
9. G. Honey, and E. Bullmore Human pharmacological MRI Trends Pharmacol. Sci. 25 2004 366 374 (Pubitemid 38829490)
10. M.C. Borras fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers J. Neurophysiol. 91 2004 2723 2733 (Pubitemid 38649778)
11. G.D. Iannetti Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans Proc. Natl. Acad. Sci. U. S. A. 102 2005 18195 18200 (Pubitemid 41798524)
12. R. Rogers An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging Anesthesiology 100 2004 292 301 (Pubitemid 38133696)
13. H. Takahashi Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study Neuroimage 27 2005 991 1001 (Pubitemid 41317266)
14. I.M. Anderson Assessing human 5-HT function in vivo with pharmacoMRI Neuropharmacology 55 2008 1029 1037
15. J.R. Tregellas Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia Neuropsychopharmacology 35 2010 938 942
16. Y.I. Sheline Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study Biol. Psychiatry 50 2001 651 658 (Pubitemid 33043767)
17. C.M. Thiel Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study Neuropsychopharmacology 27 2002 282 292 (Pubitemid 34686979)
18. R.G. Wise Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil Neuroimage 16 2002 999 1014
19. K.M. Abel Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study Neuroreport 14 2003 387 391 (Pubitemid 36337936)
20. R.G. Wise Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain Neuropsychopharmacology 29 2004 626 635 (Pubitemid 38365941)
21. N.H. Kalin Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine J. Clin. Psychiatry 58 Suppl. 16 1997 32 39 (Pubitemid 28049100)
22. R.J. Davidson The neural substrates of affective processing in depressed patients treated with venlafaxine Am. J. Psychiatry 160 2003 64 75 (Pubitemid 36042428)
23. C.H. Chen Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment Biol. Psychiatry 62 2007 407 414
24. P.J. Whalen A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder Biol. Psychiatry 63 2008 858 863 (Pubitemid 351458450)
25. J.B. Nitschke Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response Am. J. Psychiatry 166 2009 302 310
26. G.D. Iannetti, and R.G. Wise BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn. Reson. Imaging 25 2007 978 988 (Pubitemid 47081371)
27. S. Haller, and A.J. Bartsch Pitfalls in FMRI Eur. Radiol. 19 2009 2689 2706
28. N.K. Logothetis What we can do and what we cannot do with fMRI Nature 453 2008 869 878 (Pubitemid 351832564)
29. M. Leppa Acute opioid effects on human brain as revealed by functional magnetic resonance imaging Neuroimage 31 2006 661 669 (Pubitemid 43776689)
30. L. Becerra Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers Anesth. Analg. 103 2006 208 216 (Pubitemid 44036061)
31. G.D. Honey Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system Brain 126 2003 1767 1781 (Pubitemid 36917336)
32. C.H. Fu Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study Arch. Gen. Psychiatry 61 2004 877 889 (Pubitemid 39181077)
33. C.H. Fu Neural responses to happy facial expressions in major depression following antidepressant treatment Am. J. Psychiatry 164 2007 599 607 (Pubitemid 46650191)
34. K.B. Jensen Evidence of dysfunctional pain inhibition in fibromyalgia reflected in rACC during provoked pain Pain 144 2009 95 100
35. Y. Mainguy Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran Hum. Psychopharmacol. 24 Suppl. 1 2009 S19 S23
36. S.G. Mueller Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 1 2005 55 66 (Pubitemid 43348857)
37. C.R. Jack Jr. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative Alzheimers Dement. 6 2010 212 220
38. C.R. Jack Jr. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods J. Magn. Reson. Imaging 27 2008 685 691 (Pubitemid 351508080)
39. M.J. Clarkson Comparison of phantom and registration scaling corrections using the ADNI cohort Neuroimage 47 2009 1506 1513
40. J.L. Gunter Measurement of MRI scanner performance with the ADNI phantom Med. Phys. 36 2009 2193 2205
41. Schwarz, A.J. et al. (2011) A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov. Today doi:10.1016/j.drudis.2011.03.011
42. S.C. Deoni Standardized structural magnetic resonance imaging in multicentre studies using quantitative T1 and T2 imaging at 1.5 T Neuroimage 40 2008 662 671
43. T. Saam Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis J. Cardiovasc. Magn. Reson. 7 2005 799 808 (Pubitemid 41770058)
44. T. Saam Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5 T Siemens Philips, and General Electric scanners J. Magn. Reson. Imaging 26 2007 344 352 (Pubitemid 47257733)
45. S.G. Potkin, and J.M. Ford Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium Schizophr. Bull. 35 2009 15 18
46. L. Friedman Test-retest and between-site reliability in a multicenter fMRI study Hum. Brain Mapp. 29 2008 958 972
47. R.K. Lowing Differences in the interpretation of the GLP requirements by OECD monitoring authorities: the point of view from the pharmaceutical industry Ann. Ist Super. Sanita 44 2008 395 402
48. E. George Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring Drug Discov. Today 15 2010 684 689
49. P. Steiger Use of imaging biomarkers for regulatory studies J. Bone Joint Surg. Am. 91 Suppl. 1 2009 132 136
50. R.G. Wise, and C. Preston What is the value of human FMRI in CNS drug development? Drug Discov. Today 15 2010 973 980
51. L.J. Lesko Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81 2007 170 177 (Pubitemid 46174813)
52. J. Woodcock, and R. Woosley The FDA critical path initiative and its influence on new drug development Annu. Rev. Med. 59 2008 1 12 (Pubitemid 351287920)